This symposium delves into the pivotal role of type 2 inflammation in diverse skin conditions, including atopic dermatitis, prurigo nodularis, chronic spontaneous urticaria, and bullous pemphigoid. It highlights both shared and distinct disease mechanisms and patient burdens, providing crucial insights for optimizing clinical management strategies through a series of engaging panel discussions with Drs Eichenfield, Elmariah, Culton, and Hawkes.

Join Dr. Culton as she discusses the unmet treatment needs in bullous pemphigoid, and the importance of understanding pathophysiology in disease management.
Join Sanofi and Regeneron for an educational symposium on type 2 inflammation, patient characteristics predictive of disease recurrence, and emerging real-world evidence for biologics in CRSwNP.
Dr. Lara Wine Lee discusses the concept of cumulative life course impairment in AD, focusing on non-atopic comorbidities like vertical growth deficits and mental health impairment and how these might be preventable with early intervention at PeDRA 2025.

Learn about the significant burden that patients with EoE experience, and the role of type 2 inflammation in this chronic, progressive disease.

Dr. Amy Paller describes potential biomarkers of subclinical control at EADV 2025
Dr. Butler delves into the multifaceted biological mechanisms, including type 2 inflammation, that drive chronic pruritus in older adults. He explains how age-related changes contribute to epidermal barrier dysfunction, neuropathic damage, and immune decline, leading to chronic pruritus.

Join Prof. Kathryn Peterson for an expert review on how different immune cells and inflammatory mediators contribute to the pathogenesis of EoE.
Explore the role of type 2 inflammation in the production of mucus plugs in asthma and the effects these plugs can have on patients.
Watch Drs. Simpson and Armstrong explore the clinical presentations, diagnostic challenges, and significant burdens experienced by patients with atopic dermatitis and hand and foot dermatitis, as well as the role type 2 inflammation plays in both of these diseases.

Professor Klaus Rabe delves into the intricate inflammatory pathways and cellular mechanisms that drive the development and progression of COPD.

Join experts Mario Castro, Nicola Hanania, and Stephanie Christenson for an educational symposium on the real-world impact of underlying type 2 inflammation on the patient burden of asthma and COPD.